Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 5.43
CNDO's Cash to Debt is ranked higher than
71% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 20.79 vs. CNDO: 5.43 )
CNDO' s 10-Year Cash to Debt Range
Min: 2.76   Max: No Debt
Current: 5.43

Z-Score: 2.69
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -40.68
CNDO's ROE (%) is ranked higher than
66% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -21.70 vs. CNDO: -40.68 )
CNDO' s 10-Year ROE (%) Range
Min: -380.1   Max: -71.93
Current: -40.68

-380.1
-71.93
ROA (%) -32.14
CNDO's ROA (%) is ranked higher than
66% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -18.92 vs. CNDO: -32.14 )
CNDO' s 10-Year ROA (%) Range
Min: -311.1   Max: -52.49
Current: -32.14

-311.1
-52.49
ROC (Joel Greenblatt) (%) -9059.07
CNDO's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -215.73 vs. CNDO: -9059.07 )
CNDO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -106572.55   Max: -14369.48
Current: -9059.07

-106572.55
-14369.48
» CNDO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

CNDO Guru Trades in Q3 2013

Steven Cohen 402,700 sh (New)
Columbia Wanger 1,923,000 sh (+37.55%)
Paul Singer 3,731,279 sh (unchged)
» More
Q4 2013

CNDO Guru Trades in Q4 2013

Chuck Royce 530,000 sh (New)
Jim Simons 35,074 sh (New)
Paul Tudor Jones 11,300 sh (New)
Paul Singer 3,731,279 sh (unchged)
Columbia Wanger Sold Out
Steven Cohen Sold Out
» More
Q1 2014

CNDO Guru Trades in Q1 2014

Jim Simons 392,412 sh (+1018.81%)
Paul Singer 3,731,279 sh (unchged)
Chuck Royce 530,000 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q2 2014

CNDO Guru Trades in Q2 2014

George Soros 29,279 sh (New)
Jim Simons 523,900 sh (+33.51%)
Chuck Royce 530,000 sh (unchged)
Paul Singer 3,731,279 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with CNDO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-06-30 New Buy$1.55 - $2.02 $ 1.834%29279
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.12
CNDO's P/B is ranked higher than
97% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 6.41 vs. CNDO: 1.12 )
CNDO' s 10-Year P/B Range
Min: 0   Max: 61.8
Current: 1.12

0
61.8
EV-to-EBIT -0.42
CNDO's EV-to-EBIT is ranked higher than
68% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CNDO: -0.42 )
CNDO' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -0.42

Current Ratio 22.25
CNDO's Current Ratio is ranked higher than
97% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 4.31 vs. CNDO: 22.25 )
CNDO' s 10-Year Current Ratio Range
Min: 4.7   Max: 22.25
Current: 22.25

4.7
22.25
Quick Ratio 22.25
CNDO's Quick Ratio is ranked higher than
97% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 3.96 vs. CNDO: 22.25 )
CNDO' s 10-Year Quick Ratio Range
Min: 4.7   Max: 22.25
Current: 22.25

4.7
22.25

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.40
CNDO's Price/Net Cash is ranked higher than
99% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 190.00 vs. CNDO: 1.40 )
CNDO' s 10-Year Price/Net Cash Range
Min: 1.28   Max: 11.92
Current: 1.4

1.28
11.92
Price/Net Current Asset Value 1.40
CNDO's Price/Net Current Asset Value is ranked higher than
99% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 79.32 vs. CNDO: 1.40 )
CNDO' s 10-Year Price/Net Current Asset Value Range
Min: 1.28   Max: 11.92
Current: 1.4

1.28
11.92
Price/Tangible Book 1.12
CNDO's Price/Tangible Book is ranked higher than
98% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9.62 vs. CNDO: 1.12 )
CNDO' s 10-Year Price/Tangible Book Range
Min: 1.02   Max: 11.75
Current: 1.12

1.02
11.75
Earnings Yield (Greenblatt) 2040.80
CNDO's Earnings Yield (Greenblatt) is ranked higher than
99% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. CNDO: 2040.80 )
CNDO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 2584.7
Current: 2040.8

0
2584.7

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:CNB.Germany
Coronado Biosciences Inc was incorporated in Delaware on June 28, 2006. It is a biopharmaceutical company focused on novel immunotherapy biologic agents for autoimmune diseases and cancer. Its two main product candidates in clinical development are: TSO and CNDO-109. TSO, or CNDO-201, is a biologic comprising Trichuris suis ova, the microscopic eggs of the porcine whipworm. CNDO-109 is a biologic that activates the immune system's natural killer, or NK, cells to seek and destroy cancer cells. The Company faces competition from many different sources, including commercial pharmaceutical and biotechnology enterprises, academic institutions, government agencies, and private and public research institutions. Government authorities in the United States, at the federal, state and local level, and other countries regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of products.
» More Articles for CNDO

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight Jul 28 2013 
Weekly CFO Buys Highlight Jul 21 2013 
Weekly CFO Buys Highlight Jun 11 2013 
Weekly CEO Buys Highlight: CNDO Jan 21 2013 
Coronado Biosciences New CEO Makes First Buy of the Year, Worth $114K Jan 16 2013 
Weekly CEO Buys Highlight: SXL, JBSS, GNMK, CNDO, DCO Jun 30 2012 
Weekly CEO Buys Highlight: SXL, JBSS, GNMK, CNDO, DCO Jun 30 2012 

More From Other Websites
Nasdaq stocks posting largest volume increases Sep 19 2014
Kamada Plunges Following Missed Marks In Trial Sep 04 2014
CORONADO BIOSCIENCES INC Financials Aug 19 2014
CORONADO BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 11 2014
Coronado Biosciences Reports Financial Results Aug 11 2014
Coronado Falls on TSO Study Results Jun 27 2014
CORONADO BIOSCIENCES INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 26 2014
Coronado reports results from pilot study of TSO in adults with autism Jun 26 2014
Coronado Biosciences Reports Topline Results From Investigator Initiated Pilot Study of TSO in... Jun 26 2014
CORONADO BIOSCIENCES INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 17 2014
CORONADO BIOSCIENCES INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 14 2014
Coronado initiates Phase 2a clinical study of TSO for autism May 14 2014
CORONADO BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 12 2014
Coronado reports Q1 EPS (21c), one estimate (20c) May 12 2014
CORONADO BIOSCIENCES INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 14 2014
Pipeline Progress at Coronado Biosciences Apr 14 2014
CORONADO BIOSCIENCES INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 11 2014
CORONADO BIOSCIENCES INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant,... Apr 07 2014
Coronado Biosciences Reports Financial Results for the Fourth Quarter and Year Ended December 31,... Mar 14 2014
CORONADO BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 14 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK